Cannula for minimizing dilution of dosing during nitric oxide delivery

US10130783B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10130783-B2
Application numberUS-201514706449-A
CountryUS
Kind codeB2
Filing dateMay 7, 2015
Priority dateDec 4, 2012
Publication dateNov 20, 2018
Grant dateNov 20, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas, pneumatic configurations, methods of manufacturing, and methods of use, etc. are disclosed.

First claim

Opening claim text (preview).

What is claimed is: 1. A nasal cannula for therapeutic gas delivered to a patient in need thereof, the nasal cannula comprising: a first lumen, a second lumen and a cannula nosepiece: the first lumen being a nitric oxide lumen connected to a nitric oxide source, the second lumen being a trigger lumen and/or an oxygen lumen; and the first lumen and the second lumen aggregating at the cannula nosepiece, the cannula nosepiece having separate flow paths to the patient for the first lumen and the second lumen such that the nitric oxide and the oxygen do not mix in the cannula nosepiece, wherein the first lumen has an inner diameter that is smaller than the inner diameter of the second lumen but larger than an inner diameter of the flow path for the first lumen at the cannula nosepiece. 2. The nasal cannula of claim 1 , wherein the flow path for the first lumen at the cannula nosepiece comprises a first prong, a second prong and a backplane, with the first prong being in fluid communication with the second prong via the backplane and the total volume of the first prong, the second prong and the backplane being less than 0.035 mL. 3. The nasal cannula of claim 1 , wherein the nasal cannula (i) reduces dilution of one or more of the nitric oxide and the oxygen gases delivered to the patient or (ii) is configured to be placed in fluid communication with at least one system to deliver one or more of the first and second therapeutic gases to the patient, or both. 4. The nasal cannula of claim 1 , wherein the nasal cannula reduces delivery of nitrogen dioxide to the patient. 5. The nasal cannula of claim 1 , wherein the nasal cannula delivers one or more of the nitric oxide and the oxygen gases to the patient for treatment of pulmonary hypertension. 6. The nasal cannula of claim 5 , wherein the nasal cannula delivers one or more of the nitric oxide and the oxygen gases to the patient for treatment of at least one of pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD), pulmonary hypertension as pulmonary arterial hypertension (PAH), pulmonary hypertension secondary to idiopathic pulmonary fibrosis (IPF), and pulmonary hypertension secondary to sarcoidosis. 7. The nasal cannula of claim 1 , wherein the first lumen is six feet to eight feet in length having an inner diameter of 0.01 inches to 0.10 inches. 8. The nasal cannula of claim 1 , wherein the cannula comprises a wall material having a low oxygen transmission rate that is between 0.001 ⁢ ( cc ) ⁢ ( mil ) ( 24 ⁢ ⁢ hrs ) ⁢ ( 100 ⁢ ⁢ in 2 ) ⁢ ( ATM ) ⁢ ⁢ and ⁢ ⁢ 10 ⁢ ( cc ) ⁢ ( mil ) ( 24 ⁢ ⁢ hrs ) ⁢ ( 100 ⁢ ⁢ in 2 ) ⁢ ( ATM ) . 9. The nasal cannula of claim 1 , further comprising one or more of: (i) at least one check valve in fluid communication with the first lumen, (ii) a cannula key, and (iii) a scavenging material. 10. The nasal cannula of claim 1 , wherein the cannula nosepiece is further comprising a flexible support bridge that cushions the patient's the nasal septum. 11. A nasal cannula for therapeutic gas delivered to a patient in need thereof, the nasal cannula comprising: a first lumen and a second lumen: the first lumen connected to a nitric oxide source and being a combined first therapeutic gas and triggering lumen for both delivering a first therapeutic gas comprising nitric oxide to a patient and triggering, and the second lumen being a second therapeutic gas lumen for delivering comprising oxygen to the patient; the first lumen and the second lumen aggregating at a cannula nosepiece, the cannula nosepiece having separate flow paths to the patient for (i) the combined first therapeutic gas and triggering lumen and (ii) the second therapeutic gas lumen such that the first therapeutic gas and the second therapeutic gas do not mix in the cannula nosepiece; the combined first therapeutic gas and triggering lumen having an inner diameter that is smaller than an inner diameter of the second therapeutic gas lumen; and the inner diameter of the combined first therapeutic gas and triggering lumen being larger than an inner diameter of the flow path for the combined first therapeutic gas and triggering lumen at the cannula nosepiece. 12. The nasal cannula of claim 11 , wherein the flow path for the combined first therapeutic gas and triggering lumen at the cannula nosepiece comprises a first prong, a second prong and a backplane, with the first prong being in fluid communication with the second prong via the backplane and the total volume of the first prong, the second prong and the backplane being less than 0.035 mL. 13. The nasal cannula of claim 11 , wherein the nasal cannula (i) reduces dilution of one or more of the first and second therapeutic gases delivered to the patient or (ii) is configured to be placed in fluid communication with at least one system to deliver one or more of the first and second therapeutic gases to the patien

Assignees

Inventors

Classifications

  • with dilution · CPC title

  • using an oxygen concentrator · CPC title

  • Nasal cannula assemblies for oxygen therapy · CPC title

  • Oxygen · CPC title

  • Nasal cannulas or tubing (devices for improving normal breathing through the nose A61F5/08; nose filters A62B23/06; outside holding devices A61M25/02) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10130783B2 cover?
The present invention generally relates to, amongst other things, systems, devices, materials, and methods that can improve the accuracy and/or precision of nitric oxide therapy by, for example, reducing the dilution of inhaled nitric oxide (NO). As described herein, NO dilution can occur because of various factors. To reduce the dilution of an intended NO dose, various exemplary nasal cannulas…
Who is the assignee on this patent?
Mallinckrodt Hospital Products Ip Ltd
What technology area does this patent fall under?
Primary CPC classification A61M16/0677. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).